Alkermes Launches Phase 2 Study of ALKS 7290 as Adjunctive Therapy to Antidepressants in Major Depressive Disorder Patients

07:40 AM EDT, 10/30/2026 (MT Newswires) -- Alkermes (ALKS) has started a phase 2 study of ALKS 7290 as an adjunctive therapy to standard antidepressants in adults with major depressive disorder, the company said Friday. The study aims to enroll about 180 participants, who will be randomized to receive ALKS 7290 or placebo, along with antidepressant therapy, for six weeks. The study's primary goal is to evaluate the safety and tolerability of ALKS 7290, while the secondary objective is to assess whether participants taking ALKS 7290 plus antidepressant therapy experience an improvement in severity of symptoms, compared with participants taking placebo plus antidepressant therapy, the company said.